Erasca, Inc. (ERAS) Current Ratio
- Current ratio · latest quarter: Value 8.29×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 8.29× | Current assets / current liabilities. $278.44M ÷ $33.57M ≈ 8.29× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 278.44M USD | Assets, Current |
| Current obligations | 33.57M USD | Liabilities, Current |
| Cash and equivalents | 42.54M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 226.20M USD | Marketable Securities, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 2.02M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $278.44M | $33.57M | $42.54M | $226.20M | (m) | (m) | $2.02M | (m) | 8.29× |
| 2026-03-31 | $253.78M | $26.66M | $47.26M | $196.53M | (m) | (m) | $2.16M | (m) | 9.52× |
| 2025-12-31 | $286.24M | $28.51M | $73.81M | $202.27M | (m) | (m) | $981.00K | (m) | 10.04× |
| 2025-09-30 | $299.93M | $28.71M | $70.23M | $218.17M | (m) | (m) | $3.03M | (m) | 10.45× |
| 2025-06-30 | $310.66M | $28.15M | $66.14M | $234.52M | (m) | (m) | $1.66M | (m) | 11.04× |
| 2025-03-31 | $314.62M | $25.47M | $70.48M | $234.10M | (m) | (m) | $2.26M | (m) | 12.35× |
| 2024-12-31 | $308.79M | $31.39M | $67.74M | $230.57M | (m) | (m) | $468.00K | (m) | 9.84× |
| 2024-09-30 | $330.17M | $30.02M | $68.89M | $250.03M | (m) | (m) | $2.40M | (m) | 11.00× |
| 2024-06-30 | $418.00M | $24.89M | $172.80M | $235.61M | (m) | (m) | $2.14M | (m) | 16.79× |
| 2024-03-31 | $306.62M | $30.24M | $76.73M | $220.96M | (m) | (m) | $2.63M | (m) | 10.14× |
| 2023-12-31 | $320.68M | $26.16M | $93.08M | $219.28M | (m) | (m) | $2.00M | (m) | 12.26× |
| 2023-09-30 | $305.97M | $26.73M | $112.86M | $183.81M | (m) | (m) | $3.70M | (m) | 11.45× |
| 2023-06-30 | $323.85M | $23.29M | $138.79M | $178.46M | (m) | (m) | $2.63M | (m) | 13.90× |
| 2023-03-31 | $397.88M | $25.52M | $272.76M | $116.98M | (m) | (m) | $3.35M | (m) | 15.59× |
| 2022-12-31 | $444.50M | $48.69M | $284.22M | $151.40M | (m) | (m) | $23.05M | (m) | 9.13× |
| 2022-09-30 | $365.75M | $27.68M | $219.26M | $136.67M | (m) | (m) | $4.32M | (m) | 13.21× |
| 2022-06-30 | $381.42M | $22.32M | $298.01M | $73.47M | (m) | (m) | $2.29M | (m) | 17.09× |
| 2022-03-31 | $403.37M | $21.39M | $333.35M | $59.19M | (m) | (m) | $4.71M | (m) | 18.86× |
| 2021-12-31 | $420.02M | $26.22M | $360.49M | $53.99M | (m) | (m) | $4.68M | (m) | 16.02× |
| 2021-09-30 | $492.31M | $19.59M | $445.81M | (m) | (m) | (m) | $1.32M | (m) | 25.13× |
| 2021-06-30 | $197.29M | $17.91M | $156.40M | (m) | (m) | (m) | $1.51M | (m) | 11.01× |
| 2020-12-31 | $119.99M | $13.68M | $65.38M | (m) | (m) | (m) | $878.00K | (m) | 8.77× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |